Transforming the Activation of Clinical Trials

Julie T. Watters, Jason H. Pitzen, Linda J. Sanders, Virginia Nickie M. Bruce, Alissa R. Cornell, Gary C. Cseko, Janice S. Grace, Pamela S. Kwon, Andrea K. Kukla, Michael S. Lee, Michelle D. Monosmith, John D. Myren, Rebecca S. Kottschade, Marc N. Shaft, Jennifer Jenny A. Weis, Jane C. Welter, Adil E. Bharucha

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The Institute of Medicine and US Food and Drug Administration (FDA) recognize that activating clinical trials in the United States is lengthy and inefficient. Downstream consequences include increased expense, suboptimal accrual, move of clinical trials overseas, and delayed availability of treatments for patients. An in-tandem processing initiative is here highlighted that transformed the activation of clinical trials (TACT), reduced the activation time by 70%, and offers a paradigm for enhanced translational readiness.

Original languageEnglish (US)
Pages (from-to)43-46
Number of pages4
JournalClinical pharmacology and therapeutics
Volume103
Issue number1
DOIs
StatePublished - Jan 2018

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Transforming the Activation of Clinical Trials'. Together they form a unique fingerprint.

Cite this